Plasmodium immunotherapy for cancer (CAS Lamvac Biotech)
็ๅ่ซๅ ็ซ็ๆณ๏ผๅนฟๅทไธญ็ง่ๅ๏ผ
Report date: 2026/05/20 20:02:01
Base Information
Drug NamePlasmodium immunotherapy for cancer (CAS Lamvac Biotech)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesGuangzhou Zhongke Lanhua Biological Technology Co LtdGuangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences
China Registration ClassN/A
Develop Information
Active CompaniesCas Lamvac Biotech Co Ltd
Inactive CompaniesN/A
Active Indications
Inactive Indications
Other Information
ATC CodeN/A
Related LinksN/A